SIR Publishers
CENTER FOR INTERNATIONAL SCIENTIFIC PUBLICATIONS
JOURNAL OF NURSING AND WOMEN'S HEALTH
ISSN(Online): 2984-8083
Volume-9, Issue-02, Published |23-03-2026|

PULMONARY EMBOLISM: A MODERN MEDICAL ANALYSIS OF PATHOGENESIS, DIAGNOSIS, AND TREATMENT

Kibriyev Bexruz Abduraxmonovich
Email: kibriev1991@gmail.com
ORCID: https://orcid.org/0009-0002-4505-8663
Alpamisheva Saboxat Xamrokulovna
Student of General Medicine, Faculty of Medicine,
Termez University of Economics and Service

ABSTRACT

Pulmonary embolism is a life-threatening clinical syndrome situated at the intersection of internal medicine, cardiology, intensive care, and emergency medicine. In most cases it develops when thrombotic material formed in the deep veins of the lower extremities or pelvis migrates into the pulmonary arterial circulation and produces an abrupt obstruction of blood flow. The clinical importance of this disorder lies in its high early mortality, its heterogeneous presentation, and the fact that diagnostic delay remains common when symptoms are interpreted as pneumonia, acute coronary syndrome, anxiety-related dyspnea, pleurisy, or heart failure. This article analyzes pulmonary embolism from an integrated pathophysiological and clinical perspective. The review focuses on the mechanisms of venous thrombus formation, the consequences of embolic obstruction for pulmonary perfusion and right ventricular loading, the diagnostic role of clinical probability assessment, D-dimer testing, CT pulmonary angiography, echocardiography, and biomarker stratification, as well as the principles of anticoagulation, thrombolysis, catheter-directed therapy, and long-term prevention. The synthesis demonstrates that rapid recognition, structured risk stratification, and timely reperfusion or anticoagulant treatment remain the decisive factors that determine outcome.

Keywords: pulmonary artery, pulmonary embolism, venous thromboembolism, D-dimer, CT pulmonary angiography, right ventricular dysfunction, anticoagulant therapy, thrombolysis.

INTRODUCTION

Pulmonary embolism is one of the most consequential acute vascular emergencies in modern clinical medicine. Although the obstructing material is usually a thrombus, the syndrome becomes clinically important not merely because a clot exists, but because it alters ventilation-perfusion matching, increases pulmonary vascular resistance, overloads the right ventricle, and can rapidly progress toward hemodynamic collapse. A substantial proportion of fatal cases are either not recognized in time or are first confirmed after death, which makes early suspicion a central professional responsibility rather than a secondary diagnostic preference.

The difficulty begins with the fact that pulmonary embolism does not have a single defining symptom. Sudden dyspnea, pleuritic chest pain, tachycardia, syncope, hemoptysis, anxiety, unexplained hypoxemia, or isolated deterioration in exercise tolerance may all represent the disease. Small peripheral emboli may mimic pulmonary infection or musculoskeletal chest pain, whereas large central emboli can present with shock, profound hypoxemia, or cardiac arrest. Because of this variability, diagnosis must be grounded in probability-based reasoning instead of symptom recognition alone.

In current practice pulmonary embolism is assessed within a broader model of venous thromboembolism. The biological sequence begins with thrombus formation under the influence of venous stasis, endothelial injury, and hypercoagulability, then proceeds through embolization to the pulmonary circulation, acute mechanical obstruction, neurohumoral vasoconstriction, and secondary right ventricular strain. The clinical course is then shaped by clot burden, cardiopulmonary reserve, and the speed with which treatment is initiated.

The aim of this article is to provide a coherent English-language IMRAD review of pulmonary embolism by integrating pathogenesis, clinical manifestations, diagnostic algorithms, imaging findings, laboratory support, and contemporary treatment strategies into a single medical narrative that is useful for students and clinicians.

MATERIALS AND METHODS

This article was prepared as an analytical and theoretical review. The source base consisted of contemporary international clinical guidelines, open-access scientific reviews, educational resources in emergency medicine and thrombosis, and illustrative materials related to CT pulmonary angiography and diagnostic decision trees. The work does not present an original patient cohort; instead, it synthesizes established evidence and guideline-based clinical logic.

The review was organized around several consecutive analytical blocks: the pathophysiology of venous thrombosis, embolic migration into the pulmonary circulation, changes in gas exchange and hemodynamics after vascular obstruction, stratification of clinical probability, the place of D-dimer testing, the role of CT pulmonary angiography and echocardiography, biomarker-supported risk assessment, and the indications for anticoagulation, thrombolysis, catheter intervention, and long-term follow-up.

Since the article is methodological and interpretive rather than a report of original clinical research, no separate statistical processing was performed. Epidemiologic statements and practical conclusions were derived from high-quality secondary sources and harmonized across current recommendations.

RESULTS AND DISCUSSION

The analysis shows that the biological core of pulmonary embolism lies in the classical triad of venous thromboembolism: slowing of blood flow, damage to the endothelium, and a hypercoagulable state. These processes are promoted by prolonged immobilization, major orthopedic or oncologic surgery, advanced age, obesity, active cancer, pregnancy and the postpartum period, estrogen exposure, inherited thrombophilia, chronic heart failure, and a previous history of thrombosis. Under these conditions fibrin-rich thrombi usually form in the deep veins of the lower limbs or pelvis. Once detached, the embolus enters the right heart and lodges in the pulmonary arterial tree.

After obstruction of a pulmonary artery or one of its branches, perfusion immediately decreases in the affected territory. Ventilation may remain relatively preserved, but blood flow is absent or markedly reduced, creating physiological dead space. As a result, gas exchange becomes inefficient, hypoxemia may occur, and respiratory drive increases. At the same time mechanical obstruction and vasoactive mediators raise pulmonary vascular resistance. This rise in afterload places an acute burden on the right ventricle, which is anatomically thinner walled and less prepared than the left ventricle to generate high pressure. When the right ventricle dilates, interventricular septal shift reduces left ventricular filling and systemic blood pressure may fall sharply.

This mechanism explains why the severity of pulmonary embolism is determined not only by clot size but by the interaction between embolic burden and cardiopulmonary reserve. A relatively modest embolic event can destabilize a patient with preexisting heart or lung disease, whereas a previously healthy patient may tolerate a larger clot for a limited period. In massive embolism the result may be obstructive shock or sudden death. In intermediate-risk disease the patient may remain normotensive but exhibit right ventricular dysfunction and elevated cardiac biomarkers, indicating myocardial strain.

Clinically, pulmonary embolism presents across a broad spectrum. The most frequent complaints are sudden shortness of breath, pleuritic chest pain, tachycardia, and an internal sense of

distress or fear. Segmental and subsegmental emboli may produce localized pleuritic pain, cough, mild fever, or hemoptysis due to pulmonary infarction, while central emboli more often cause syncope, cyanosis, severe hypoxemia, systemic hypotension, or circulatory collapse. Physical examination may be unrevealing; therefore, normal auscultation or a nonspecific chest radiograph should never be used to exclude the disease.

Risk factor analysis remains essential because prevention begins before embolization occurs. Hospitalized and postoperative patients require special vigilance, particularly after prolonged bed rest, trauma, lower extremity fracture, pelvic surgery, spinal cord injury, or cancer treatment. In ambulatory care, clinicians should also remember the contribution of oral contraceptives, hormone therapy, inherited coagulation disorders, inflammatory disease, and long-distance travel when combined with additional risk factors. Accurate recognition of this background sharply improves the quality of diagnostic reasoning.

Modern diagnosis does not begin with imaging but with estimation of pretest probability. Tools such as the Wells score or Geneva score help separate patients with low, intermediate, or high clinical probability. In hemodynamically stable patients with low or intermediate probability, D-dimer testing serves as an efficient exclusion tool because a negative result makes clinically significant pulmonary embolism unlikely. In contrast, a positive D-dimer is nonspecific and must be followed by imaging. In hemodynamically unstable patients, the diagnostic pathway shifts toward urgent bedside evaluation and immediate imaging or treatment-oriented decisions.

If clinical probability is high or D-dimer is positive, CT pulmonary angiography is the principal imaging method. Its strength lies in the direct visualization of intraluminal filling defects, the ability to estimate clot distribution, and the additional possibility of assessing right ventricular enlargement and alternative thoracic diagnoses. The first figure included in this article demonstrates a saddle embolus located at the bifurcation of the pulmonary artery, a finding associated with a potentially severe hemodynamic burden depending on ventricular response.

CT pulmonary angiography also contributes to risk stratification. An increased right ventricle-to-left ventricle diameter ratio, delayed contrast transit, and central clot burden all suggest significant right-sided pressure overload. Echocardiography is particularly useful in unstable patients because it can rapidly reveal right ventricular dilatation, hypokinesis, pressure overload, and signs that support emergency reperfusion strategies even when immediate CT is difficult to obtain.

Laboratory support has a complementary role. Cardiac troponin and BNP or NT-proBNP increase when the right ventricle experiences ischemia or wall stress. In normotensive patients these markers help identify intermediate-risk disease and refine prognosis. However, none of these markers should be interpreted in isolation; their value emerges only when integrated with symptoms, hemodynamics, and imaging findings.

Treatment begins with prompt anticoagulation unless contraindications dominate the risk-benefit balance. Low-molecular-weight heparin, fondaparinux, unfractionated heparin, or direct oral anticoagulants are selected according to hemodynamic state, renal function, procedural needs, pregnancy status, and bleeding risk. Anticoagulation prevents further thrombus extension and reduces the probability of recurrent embolization. In most hemodynamically stable patients it remains the foundation of therapy.

In high-risk pulmonary embolism accompanied by shock, persistent hypotension, or cardiac arrest, systemic thrombolysis can be life-saving because it rapidly restores pulmonary perfusion and unloads the right ventricle. Its use is limited by the risk of major bleeding, including intracranial hemorrhage, so strict assessment of contraindications is mandatory. Where systemic thrombolysis is

SIR Publishers
CENTER FOR INTERNATIONAL SCIENTIFIC PUBLICATIONS
JOURNAL OF NURSING AND WOMEN'S HEALTH
ISSN(Online): 2984-8083
Volume-9, Issue-02, Published |23-03-2026|

unsuitable or ineffective, catheter-directed reperfusion or surgical embolectomy may be considered in specialized centers.

The second figure summarizes the modern diagnostic logic for suspected pulmonary embolism. The algorithm separates hemodynamically unstable patients from stable ones, then routes evaluation through echocardiography, clinical probability scoring, D-dimer testing, and CT pulmonary angiography. This staged structure is important because it reduces both dangerous delay and unnecessary imaging.

Long-term consequences must also be considered. In some patients thrombotic material does not resolve completely, and chronic thromboembolic pulmonary hypertension develops. These patients continue to suffer from exertional dyspnea, reduced exercise capacity, and progressive right heart strain. Therefore follow-up is not a bureaucratic formality but a biologically justified continuation of care.

The most important teaching conclusion is that time is the decisive variable in pulmonary embolism. Success depends on rapid suspicion, disciplined probability assessment, targeted use of D-dimer, timely imaging, correct risk stratification, and immediate initiation of anticoagulation or reperfusion therapy when indicated. Any approach that relies on waiting for a perfectly classical presentation is unsafe, because the disease often advances faster than diagnostic certainty.



Figure 1. CT pulmonary angiography showing a saddle embolus at the pulmonary artery bifurcation.



Figure 2. Diagnostic algorithm for suspected pulmonary embolism based on hemodynamic status and clinical probability.

CONCLUSION

Pulmonary embolism is a life-threatening disorder that requires urgent recognition and structured management. Its pathogenesis is rooted in venous thrombosis, embolic migration into the pulmonary circulation, disturbance of perfusion, impairment of gas exchange, and acute right ventricular overload. The clinical picture is often nonspecific, which is why probability-based reasoning must guide diagnosis.

The most reliable modern approach combines clinical probability assessment with selective D-dimer testing, CT pulmonary angiography, echocardiography in unstable patients, and biomarker-supported risk stratification. Anticoagulation remains the central therapeutic principle, while thrombolysis or invasive reperfusion is reserved for patients with high-risk disease or carefully selected intermediate-high-risk cases.

The decisive factor in outcome is not only the availability of advanced technology, but the clinician's ability to suspect pulmonary embolism early and to act without unnecessary delay. For that reason pulmonary embolism should be understood as both a diagnostic challenge and a time-critical therapeutic emergency.

REFERENCES

1. Konstantinides S.V., Meyer G., Becattini C., et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society. European Heart Journal. 2020;41(4):543-603.
2. Vyas V., Goyal A., Bansal P. Acute Pulmonary Embolism. In: StatPearls. Treasure Island: StatPearls Publishing; 2025.
3. van Es N., Kraaijpoel N., Klok F.A., et al. Diagnostic management of acute pulmonary embolism. Journal of Thrombosis and Haemostasis. 2024;22.
4. Peracaula M., Goycoolea A., Saldías F. Decoding pulmonary embolism: pathophysiology, diagnosis, and emerging management strategies. 2024.
5. Centers for Disease Control and Prevention. About Venous Thromboembolism and Risk Factors for Blood Clots. 2024-2025.
6. Moore A.J.E., Wachsmann J., Cham M.D., et al. Imaging of acute pulmonary embolism: an update. Cardiovascular Diagnosis and Therapy. 2018;8:225-243.

JOURNAL OF NURSING AND WOMEN'S HEALTH
ISSN(Online): 2984-8083
Volume-9, Issue-02, Published |23-03-2026|

7. Erythropoulou-Kaltsidou A., Koniari I., Velissaris D. New guidelines for the diagnosis and management of pulmonary embolism: key changes. World Journal of Cardiology. 2020;12:161-166.
8. Wong K.J., Kushnir M., Billett H.H. Saddle pulmonary embolism: demographics, clinical presentation, and outcomes. Critical Care Explorations. 2021;3.